Current trial data suggest that many MCED tests demonstrate high specificity, often above 99% thereby reducing the likelihood of false positives ...

Rheumatologist Dr Thomas Batty and haematologist Dr Emma Conway O'Brien describe a rational approach to investigating multifocal pain ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...

The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.

CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

Researchers at Mass General Brigham have demonstrated the technical feasibility of using ultra-low field (ULF) magnetic resonance imaging (MRI) for breast imaging. With further refinement and ...